

ISSN: 2776-1010 Volume 2, Issue 11, Nov, 2021

THE SIGNIFICANCE OF P₅₃ IHC AS A MARKER IN DIAGNOSIS AND PROGNOSIS IN LOW GRADE AND HIGH GRADE UROTHELIAL CANCER

Eaman suud khalifa Lecturer, Pathology Department College of Medicine, Mustansiriyah University, Baghdad, Iraq

Abstract Background :

One of the most important approach for the diagnosis and determination of patient prognosis in urothelial cancer is the microscopical classification of papillary carcinoma. Overlap in the extent of the tumor may leads to some difficulties in the diagnosis of the tumor , so it is illogical to depend on morphology alone.

Objective :

We aimed in this paper to to evaluate P53 as an immunohistochemical marker and compared with pathological findings for the diagnosis and prognosis of urothelial cancer.

Methods:

Our study was conducted in Ghazi Al-Hariri hospital. Baghdad , Iraq , during the period between March and September, 2021 . Samples from Urinary bladder were collected from 35 patient with urothelial carcinoma who had undergone surgery. Biopsy samples referred to histopathology department. Immunohistochemical Staining of P53 was performed and correlated to the histopathological indices of the tumor.

Results:

Out of 35 cases , 20 patients were diagnosed as a low grade and 15 patients as a high grade urothelial carcinomas . P53 specificity was 87% , while the sensitivity was 46% . There was a positive correlation noted between immunohistochemical findings and tumor grade . Out of 15 cases of high grade tumor , 11 cases had strong positive p53 staining , three cases had weak staining , and one case of high grade was negative . Out of twenty cases of low grade tumor , 15 cases were weak staining for p53 stain, three cases had strong p53 stain, and two cases were negative.

Conclusion: Addition of p53 immunohistochemical staining to the morphology can be helpful in the diagnosis and prognosis of patient with urothelial carcinomas .

Keywords: urothelial cancer, p53, grade, immunohistochemistry.



ISSN: 2776-1010 Volume 2, Issue 11, Nov, 2021

Introduction

Urothelial cancer is one of the commonest malignancies worldwide . About 336,000 new cases being diagnosed yearly. This malignancy can occurs in both sexes and at any age but it predominantly affects middle and old age males. There are many risk factors participate in the development of urothelial carcinoma , the most common one is smoking. In smokers, the risk of urothelial carcinoma is higher than that in general population (3 -5-fold).

The incidence showed a declining approximately 1.6 fold after discontinuation of smoking (1-7). The role of cigarette smoking in the development of bladder cancer is still not clear. There are many carcinogenic factors have been discovered in tobacco (e.g , arylamine, oxygen free radicals and 4-aminobenzyle) (8- 12). Other responsible factors like drugs (e.g , analgesia, cyclophosphamide), chemicals ,diet rich in fat, and arsenic-containing water, also reported as causative agents. additionally , chronic infections (schistosomiasis), fungi, radiation and stones might be predisposing factors (13). Hematuria is the predominant presenting symptom . Twenty percent of patients with gross hematuria have been diagnosed as urothelial cancer , while this diagnosed was given for about 10% of patients with microscopic hematuria (14-17).

According to World Health Organization (WHO), urothelial carcinomas are classified into low and high grades (18-20). This classification which is generally accepted (25,30), is basically depend on the degree of anaplasia which is characterized by "hypercellularity, hyperchromasia, loss of cell polarity and loss of cell differentiation from the basement membrane to the cell surface, nuclei pleomorphism, variation in cell size, abnormal mitosis, chromatin pattern, , and giant cell formation" (21-24). From the clinical point of view, for each tumor type there is a specific treatment line and eventually this will affect patient prognosis. One of the common problems in the diagnosis of urothelial carcinomas is the overlap between the grades of the tumor, therefore, the precise microscopical diagnosis of the carcinoma is not all the time straight forward. So, we need additional methods to distinguish between low and high grades of the tumor.

The aim of our study was to accurately assess the tumor grade by using P53 immunohistochemistry (IHC) in correlation with the morphological findings to affirm the diagnosis and eventually select a specific management line and better follow-up approach .

Material and Methods

This study was conducted in Ghazi Al-Hariri teaching hospital , Baghdad , Iraq during the period from March to September, 2021. Samples Selected and taken from 35 patients with bladder cancer who underwent surgery. Biopsy samples referred to histopathology department. Demographic information was recorded. The biopsy samples were selected , 20 low grade and 15 high grade cases were included. P53 IHC staining and the histopathologic findings were assessed (in relation to the tumor grade wether low or high). Immunohistochemical Staining and P53 expression was completed "by using the KIT (anti- p53) polyclonal antibody (1:500,DAKO,carpinteria,CA) with 4-µm cut sections thickness of tissue. Deparaffinization, rehydration , antigen unmasking by boiling and then using of 3% H2O2 for 20 minutes to inhibit internal peroxidase activity".



ISSN: 2776-1010 Volume 2, Issue 11, Nov, 2021

P53 positive and negative cut-off points were categorized according to the intensity of staining and suitability of cells (percentages of cytoplasmic and nuclear staining) as follows :

Positive staining : cell staining >5%.

Mild Staining : cell staining 5-10 % .

Strong staining : cell staining > 50%.

Moderate staining in between these ranges (5).

Statistical Analysis : "Statistical significance was determined by Fisher's and Chi-square analysis for categorical variables". "categorical data were described as frequency (%) with a 95% confidence interval in 5 normal groups. Chi-square test was also used to analyse the difference between the indices".

Results

Out of 35 patients , 30 patients were males and 5 patients were females. The mean age was 55.6 \pm 11.6 year.

Table-1 showes the relation ship between the intensity of P53 staining and the tumor grade .

Out of 15 cases of high grade tumor, 11 cases had a strong positive p53 staining , three cases had a weak staining, and one case was negative.

Out of twenty cases of low grad tumor, 15 cases had a weak staining for p53 stain, three cases had a strong p53 staining , and two cases had a negative staining . Furthermore, there was no statistically significant linkage noted between the tumor depth of invasion and P53 expression (Table 2).

P53 specificity was 87% with a low sensitivity (46%) comparing with low and high morphological parameters of the tumor. Positive predictive value was 72.5% and negative predictive value was 65.6%. So; P53 intensity of expression were very important for urothelial carcinomas diagnosis, meanwhile; negative results were not determinant .

Discussion

P53 tumor suppressor gene mutation have been reported in many types of malignancies . In urothelial cancer · P53 overexpression is thought to be linked to worse prognosis. Inspite of a large number of reports , still there is a confusion regarding this subject, P53 immunohistochemical staining was performed on biopsy samples after making slides and staining. According to the results, P53 specifity was 87% for the low- and high-grade papillary carcinomas, and the sensitivity was 46%. In addition, there were a strong association between the immunohistochemical stain and the grade of the tumor, but there was no a statistically significant correlation noted with the muscle depth of invasion . Many previous studies in the same field investigate the diagnostic and prognostic role of P53 in urothelial carcinomas . In Toll et al. study, "invasive and non-invasive cases of papillary carcinoma were immunohistochemically stained for Ki67, P53, E-Cadherin, and CK20" and they reported that, there was no a statistically significant difference noted between the invasive and non-invasive tumors concerning IHC staining (31).

In Roychowdhury et al. study, "P53 staining was performed on high and low grade papillary carcinoma cases. They found that the expression of P53 plays an important role in suppression.of neoplastic



ISSN: 2776-1010 Volume 2, Issue 11, Nov, 2021

transformation by cell cycle arrest or apoptosis so it work as tumor suppressor gene". (32). Additionally, Anadi et al. reported in their study that "P53 marker was strongly associated with the expression of high- and low-grade tumors" (33). Also , Shim et al. found that "immunohistochemically analysed the Ki67, P53, and CK20 markers. They observed that tumor grade and IHC results were significantly associated only for Ki67" (34).

Furthermore ; Mumtaz et al. Reported "a significant association between the grade of the tumor and IHC results (P53 and CK20 staining in both high and low-grade papillary carcinomas)" (5).

In Rajcani et al., study, "IHC analyses of Ki67, HMWCK, and P53 in cases of bladder carcinoma and chronic bladder inflammation showed a significant correlation between tumor grade and Ki67 and HMWCK markers". Additionally, they reported a positive P53 in premalignant changes of chronic inflammation (3).

Conclusion

According to our study which was consistent with most of previous reports , p53 specifity was 87% with low sensitivity (46%) comparing with low and high morphological parameters of papillary carcinoma . So ; positive values and the intensity of staining are important for the diagnosis and prognosis of urothelial carcinomas , but their negative values are not determinant.

Acknowledgements

I would like to thank all the staff of pathology department in Ghazi Al- Hariri hospital.

Conflict of Interest

No conflict of interest was reported.

Table 1: Expression of P53 with the grade of the tumor.

Tumor grade	P53 express	P value		
	Negative	Weak positive	Strong positive	
High grade	1	3	11	
Low grade	2	15	3	0.001
Total	3	18	14	


	• • • •	1 • • • •
Table-2 : Expression of P53	in relation to muscu	laris propria invasion
Tuble 2. Expression of 1.00	in relation to masca	

	1	00	1 1	
P53 expression	muscularis propria invasion			P value
	Present	Absent	Muscularis propria not present	
Negative	1	2	0	
Weak positive	6	10	2	
Strong positive	4	9	1	0.23
Total	11	21	3	



ISSN: 2776-1010

Volume 2, Issue 11, Nov, 2021



Figue-1: P53 IHC in low grade urothelial carcinoma (mild nuclear staining,10x)




Figure-2: P53 IHC in High grade papillary urothelial carcinoma (strong nuclear stain,10x)



ISSN: 2776-1010 Volume 2, Issue 11, Nov, 2021

References

1. Bertz S, Otto W, Denzinger S, Wieland WF, Burger M, Stöhr R, et al. Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1

 rothelial bladder cancer. Europ Urol. 2014;65(1):218-26. [DOI:10.1016/j.eururo.2012.05.033]
[PMID] Kolahdoozan Sh, Sadjadi A, Radmard AR, Khademi H. Five Common Cancers in Iran. Arch Iran Med. 2010;13(2):143-6.

3. Hodges KB, Lopez-Beltran A, Davidson DD, Montironi R, Cheng L. Urothelial dysplasia and other flat lesions of the urinary bladder: clinicopathologic and molecular features. Human Pathol. 2010;41:155-62. [DOI:10.1016/j.humpath.2009.07.002] [PMID]

4. Ohsawa I, Nishimura T, Kondo Y, Kimura G, Satoh M, Matsuzawa I, et al. Detection of urine survivin in 40 patients with bladder cancer. J Nippon Med Sch. 2004;71(6):379-83. [DOI:10.1272/jnms.71.379] [PMID]

5. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. [DOI:10.3322/caac.21492] [PMID]

6. Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder cancer incidence and mortality: a global overview and recent trends. European urology. 2017;71(1):96-108. [DOI:10.1016/j.eururo.2016.06.010] [PMID]

7. Asgari M, Maybodi MN, Abolhasani M. Differential diagnosis of urothelial carcinoma in situ from non-neoplastic urothelia: Analysis of CK20, CD44, P53 and Ki67. Med J Islam Repub Iran. 2016;30:400.

8. Rajcani J, Kajo K, Adamkov M, Moravekova E, Lauko L, Felcanova D, et al. Immunohistochemical characterization of urothelial carcinoma. Bratislavske Lekarske Listy. 2013;114(8):431-8. [DOI:10.4149/BLL_2013_091] [PMID]

9. Khayamzadeh M, Aliakbari F, Zolghadr Z, Emadeddin M, Ahadi M, Akbari ME, Abedi AR, Nematollahi Sh, Hosseini SJ. Five-year Survival Rate of Bladder Cancer in Iran during 2001-2007. Iran J Pathol, 2020.118375.2287 [DOI:10.30699/ijp.2020.118375.2287] [PMID] [PMCID]

10. Mai KT, Flood TA, Williams P, Kos Z, Belanger EC. Mixed low-and high-grade papillary urothelial carcinoma: histopathogenetic and clinical significance. VirchowsArchiv. 2013;463(4):575-81. [DOI:10.1007/s00428-013-1456-7] [PMID]

11. Shariat SF, Ashfaq R, Karakiewicz PI, Saeedi O, Sagalowsky AI, Lotan Y. Survivin expression is associated with bladder cancer presence, stage, progression, and mortality. Cancer: Interdisciplin3. nt J Am Cancer Soc. 2007;109(6):1106-13 [DOI:10.1002/cncr.22521] [PMID]

12. Mumtaz S, Hashmi AA, Hasan SH, Edhi MM, Khan M. Diagnostic utility of p53 and CK20 immunohistochemical expression grading urothelial malignancies. Int Arch Med. 2014;7(1):36. [DOI:10.1186/1755-7682-7-36] [PMID] [PMCID]

13. Hasan IA, Gaidan HA, Al-kaabi MM. Diagnostic value of immunohistochemical panel (Cytokeratin CK 7, Cytokeratin CK20, High molecular weight cytokeratin HMWCK (clone CK34βE12) and Prostatic



ISSN: 2776-1010 Volume 2, Issue 11, Nov, 2021

specific antigen (PSA) in differentiation between poorly differentiated prostatic and urothelial carcinoma. Iraq J Cancer Med Gen. 2018;11(1):7-13.

14. Weyerer V, Schneckenpointner R, Filbeck T, Burger M, Hofstaedter F, Wild PJ, et al. Immunohistochemical and molecular characterizations in urothelial carcinoma of bladder in patients less than 45 years. J Cancer. 2017;8(3):323. [DOI:10.7150/jca.17482] [PMID] [PMCID]

15. Buolamwini JK & et al.: Small molecule antagonists of the MDM2 oncoprotein as anticancer agents. Curr Cancer Drug Target. 2005, Feb;5(1):57-68 [DOI:10.2174/1568009053332672] [PMID]

16. McKenney J, Desai S, Cohen C, Amin MB. Discriminatory Immunohistochemical Staining ofUrothelial Carcinoma in Situ and Nonneoplastic Urothelium. Am J Surg Pathol. 2001;25(8):1074-8. [DOI:10.1097/00000478-200108000-00013] [PMID]

17. Cumberbatch MGK, Noon AP. Epidemiology, aetiology and screening of bladder cancer. Transl Androl Urol. 2019;8(1):5-11. [DOI:10.21037/tau.2018.09.11] [PMID] [PMCID]

18. Yang Y, Kaimakliotis HZ, Williamson SR, Koch MO, Huang K, Barboza MP, et al., editors. Micropapillaryurothelial carcinoma of urinary bladder displays immunophenotypic features of luminal and p53-like subtypes and is not

19. Korkolopoulou P: The role of p53, mdm2, and b-2 oncoproteins, epidermal growth factor receptor and prolifration markers in the prognosis of urinary bladder cancer. Patol Res Pract 1997,193(11 - 12):767-75 [DOI:10.1016/S0344-0338(97)80055-6]

20. Das D, Dey RK, Saha S, Das TK. Utility of a dual immunostain like p53 and CK20 to aid in the diagnosis and categorization of neoplastic bladder biopsies. J Evol Med Den Sci-JEMDS. 2015;4(25):4261-9. [DOI:10.14260/jemds/2015/616]

21. Barth I, Schneider U, Grimm T, Karl A, Horst D, Gaisa NT, et al. Progression of urothelial carcinoma in situ of the urinary bladder: a switch from luminal to basal phenotype and related therapeutic implications. Virchows Archiv. 2018;472(5):749-58. [DOI:10.1007/s00428-018- 2354-9] [PMID] [PMCID]

22. Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO classification of tumours of the urinary system and male genital organs-part B: prostate and bladder tumours. Eur Urol. 2016;70(1):106-19. [DOI:10.1016/j.eururo.2016.02.028] [PMID]

23. Chou R, Gore JL, Buckley D, Fu R, Gustafson K, Griffin JC, et al. Urinary Biomarkers for Diagnosis of Bladder Cancer: A Systematic Review and Meta-analysis. Ann Intern Med. 2015;163(12):922-31. [DOI:10.7326/M15-0997] [PMID]

24. Koletsas N, Koletsa T, Choidas S, Anagnostopoulos K, Touloupidis S, Zaramboukas T, et al. Immunohistochemical Investigation of HER/AKT/mTOR Pathway and Cellular Adhesion Molecules in



ISSN: 2776-1010 Volume 2, Issue 11, Nov, 2021

Urothelial Carcinomas. Patholog Res Int. 2017:6794150. [DOI:10.1155/2017/6794150] [PMID] [PMCID]

25. EL-RASHIDY M, AYA S. Immunohistochemical Study of the Role of CK20, p53 and Ki-67 in Differentiation of Some Urothelial Lesions and Urothelial Carcinoma of the Urinary Bladder. Med J Cairo Uni. 2018;86(September):2687-95. [DOI:10.21608/mjcu.2018.59607]

26. Sanli O, Dobruch J, Knowles MA, Burger M, Alemozaffar M, Nielsen ME, et al. Bladder cancer. Nature reviews Dis primers. 2017;3(1):1-19. [DOI:10.1038/nrdp.2017.22] [PMID] Vol.16 No. 3 Summer 2021 IRANIAN JOURNAL OF PATHOLOGY Mahsa Ahadi et al. 30

27. Yikilmaz TN, Dirim A, Ayva ES, Ozdemir H, Ozkardes H. Clinical use of tumor markers for the detection and prognosis of bladder carcinoma: A comparison of CD44, cytokeratin 20 and survivin. Urol J. 2016;13(3):2677-83.

28. Kamat AM, Hahn NM, Efstathiou JA, Lerner SP, Malmström PU, Choi W, et al. Bladder cancer. The Lancet. 2016;388(10061):2796-810. [DOI:10.1016/S0140-6736(16)30512-8]

29. Uchida t: Clinical significance of p53, mdm2 and bci2 expression in transitional cell carcinoma of bladder. Oncol Rep, 2002, marapr,9(2),253-9. [DOI:10.3892/or.9.2.253]

30. Hashimoto h: Role of p53 and mdm2 in tumor proliferation and determination of the prognosis of TCC of renal pelvises and ureter. Int J Urol 2000, Dec, 7(12),457-63. [DOI:10.1046/j.1442-2042.2000.00230.x] [PMID]

31. Toll AD, Epstein JI. Invasive low-grade papillary urothelial carcinoma: a clinicopathologic analysis of 41 cases. The American journal of surgical pathology. 2012;36(7):1081-6. [DOI:10.1097/PAS.ob013e318253d6e0] [PMID]

32. Roychowdhury A, Dey R, Bandyapadhyay A, Bhattacharya P, Mitra R, Dutta R. Study of mutated p53 protein by immunohistochemistry in urothelial neoplasm of urinary bladder. J Indian Med Assoc. 2012;110(6):393-6.

33. Anadi RC, Dey RK. Expression of p53 Protein by Immunohistochemistry in Urothelial Neoplasm: A Hospital-based Study from Eastern India.

34. Shim J-W, Cho KS, Choi Y-D, Park Y-W, Lee DW, Han W-S, et al. Diagnostic algorithm for papillary urothelial tumors in the urinary bladder. Virchows Archiv. 2008;452(4):353-62. [DOI:10.1007/s00428-008-0585-x] [PMID] [PMCID]

35. Moradi Tabrizi H, Nazar E, Ahmadi SA, Azimi E, Majidi F. Survivin and Her2 Expressions in Different Grades of Urothelial Neoplasms of Urinary Bladder. Iran J Pathol. 2021; 16(2): 154-161 [DOI:10.30699/ijp.2020.130859.2447] [PMID] [PMCID]

36. Jalali Nadoushan MR, Ghorbanian E, Taheri T. Relationship between grade and MDM2 oncoprotein overexpression in transitional cell carcinoma of the urinary bladder. Iran J Pathol, (2006)1, (1), 17-20